Lakewood Amedex Biotherapeutics Inc (LABT)

May 24, 2026

Lakewood-Amedex stock falls despite positive Nu-3 manufacturing update - MSN

May 24, 2026

May 23, 2026

Lakewood-Amedex Biotherapeutics Inc. Reports Q1 2026 Financial Results and Advances in Antimicrobial Therapy Development - Minichart

May 23, 2026

May 22, 2026

Lakewood-Amedex Biotherapeutics Inc. 1Q 2026: Revenue ($886.75K), EPS ($0.2) — 10-Q Summary - TradingView

May 22, 2026

May 22, 2026

LABT SEC FilingsLakewood-Amedex 10-K, 10-Q, 8-K Forms - Stock Titan

May 22, 2026

May 20, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

May 20, 2026

May 20, 2026

LABT News | LAKEWOOD-AMEDEX BIOTHERAPEUT (NASDAQ:LABT) - ChartMill

May 20, 2026

May 19, 2026

Lakewood-Amedex Biotherapeutics(LABT) Stock Options Chain | Quotes & News - Moomoo

May 19, 2026

May 19, 2026

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) AI-Powered Stock Analysis - Meyka

May 19, 2026

May 19, 2026

Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers - Sahm

May 19, 2026

May 19, 2026

Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update - Sahm

May 19, 2026

May 18, 2026

Lakewood-Amedex Biotherapeutics advances production of foot ulcer candidate Nu3 - TipRanks

May 18, 2026

May 18, 2026

Positive Nu-3 Data Advances Lakewood-Amedex Toward Phase 2 Diabetic Foot Ulcer Trial (LABT) - Yahoo Finance

May 18, 2026

May 18, 2026

Lakewood-Amedex completes manufacturing steps for Nu-3 trial By Investing.com - Investing.com South Africa

May 18, 2026

May 18, 2026

LABT Stock Slides As Volatility Grips Biotech Micro-Cap - StocksToTrade

May 18, 2026

May 18, 2026

Lakewood-Amedex Provides Progress Update Of Nu-3 In Diabetic Foot Ulcers; Stock Down - RTTNews

May 18, 2026

May 18, 2026

Lakewood-Amedex Biotherapeutics Announces Positive Data For The Advancement Of Lead Candidate, Nu-3 - TradingView

May 18, 2026

May 18, 2026

LABT Stock Slides As Volatility Tests Biotech Day Traders - timothysykes.com

May 18, 2026

May 18, 2026

Lakewood-Amedex completes manufacturing steps for Nu-3 trial - Investing.com

May 18, 2026

May 18, 2026

LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC

May 18, 2026

May 18, 2026

Lakewood-Amedex Biotherapeutics Inc (LABT) Stock Price, Quote, News & History - Benzinga

May 18, 2026

May 17, 2026

Lakewood-Amedex jumps 20% in Nasdaq market debut - MSN

May 17, 2026

May 15, 2026

LABT Should I Buy - Intellectia AI

May 15, 2026

May 14, 2026

Lakewood‑Amedex (LABT) registers 9.65M shares tied to Series C conversion - Stock Titan

May 14, 2026

May 14, 2026

[EFFECT] Lakewood-Amedex Biotherapeutics Inc. SEC Filing - Stock Titan

May 14, 2026

May 14, 2026

LABT Stock Price, Quote & Chart | LAKEWOOD-AMEDEX BIOTHERAPEUT (NASDAQ:LABT) - ChartMill

May 14, 2026

May 12, 2026

Lakewood-Amedex selects PERI as CRO for Nu-3 phase 2 trial - Investing.com UK

May 12, 2026

May 12, 2026

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to - GuruFocus

May 12, 2026

May 12, 2026

Lakewood-Amedex selects PERI as CRO for Nu-3 phase 2 trial By Investing.com - Investing.com South Africa

May 12, 2026

May 12, 2026

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 - PR Newswire

May 12, 2026

May 10, 2026

Lakewood-Amedex (LABT) Stock Analysis Report | Financials & Insights - Benzinga

May 10, 2026

May 08, 2026

Lakewood-Amedex Biotherapeutics Inc. (LABT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

May 08, 2026

May 07, 2026

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) Competitors - Meyka

May 07, 2026

May 07, 2026

This newly listed biotech is soaring – retail says $14 is the line in the sand - MSN

May 07, 2026

May 07, 2026

Number of shareholders of Lakewood-Amedex Biotherapeutics Inc. – NASDAQ:LABT - TradingView

May 07, 2026

May 06, 2026

Lakewood-Amedex Biotherapeutics (LABT) director files Form 3 with zero shares - Stock Titan

May 06, 2026

May 05, 2026

Lakewood-Amedex reports promising AMR data for Nu-3 in iDFU - Clinical Trials Arena

May 05, 2026

May 02, 2026

Lakewood Amedex Advances Nu 3 Bisphosphocin Candidate With Strong AMR Resistance Profile - BioPharma APAC

May 02, 2026

May 01, 2026

Lakewood-Amedex (LABT) director lists stock and warrant holdings - Stock Titan

May 01, 2026

May 01, 2026

Lakewood-Amedex (LABT) Chief Medical Officer reports stock and option holdings - Stock Titan

May 01, 2026

May 01, 2026

LABT CEO Kelvin Cooper discloses 300,594 shares and options in Form 3 - Stock Titan

May 01, 2026

May 01, 2026

Lakewood-Amedex (LABT) CFO reports 468K shares and large option grants - Stock Titan

May 01, 2026

May 01, 2026

Lakewood-Amedex (LABT) S-1 resale tied to Series C funding and Nu-3 - Stock Titan

May 01, 2026

May 01, 2026

Biotech Stocks To Follow TodayMay 1st - MarketBeat

May 01, 2026

May 01, 2026

LABT Stock Volatility Draws Traders After Sharp Pullback - StocksToTrade

May 01, 2026

May 01, 2026

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data For Lead Candidate Targeting Infected Diabetic Foot Ulcers - TradingView

May 01, 2026

May 01, 2026

LABT Stock Slides As Volatility Grips Thinly Capitalized Biotech - timothysykes.com

May 01, 2026

May 01, 2026

Lakewood-Amedex reports resistance data for diabetic ulcer drug By Investing.com - Investing.com South Africa

May 01, 2026

May 01, 2026

Lakewood-Amedex Biotherapeutics’ lead candidate in foot ulcers shows efficacy - TipRanks

May 01, 2026

May 01, 2026

$Lakewood-Amedex Biotherapeutics (LABT.US)$ Hopefully I'll have some sweet dreams tonight. - Moomoo

May 01, 2026

May 01, 2026

Lakewood-Amedex reports resistance data for diabetic ulcer drug - Investing.com

May 01, 2026

May 01, 2026

In 21-day lab tests, Nu-3 stayed active against resistant bacteria - Stock Titan

May 01, 2026

May 01, 2026

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers - Quantisnow

May 01, 2026